CJC-1295 (No DAC) + GHRP-2 – 5mg / 5mg (3ml Pen)

CJC-1295 No DAC + GHRP-2 5mg/5mg – Growth Hormone Research Peptide Blend

CJC-1295 No DAC + GHRP-2 is a dual-peptide research formulation combining a growth hormone-releasing hormone (GHRH) analogue with a growth hormone secretagogue. Supplied in a 3ml pen containing 5mg of each compound, this combination is investigated for its effects on growth hormone signalling, pituitary activity and endocrine pathways associated with muscle development and metabolic regulation.

The two peptides interact with different receptor systems, making their combined activity particularly relevant to research examining growth hormone secretion and hormonal signalling.

CJC-1295 + GHRP-2 and Muscle Growth Research

Growth hormone plays an important role in protein metabolism, tissue development and the regulation of processes associated with muscle physiology.

CJC-1295 No DAC acts on GHRH receptors, while GHRP-2 activates ghrelin receptors (GHS-R1a). These complementary mechanisms have attracted research interest because stimulating both pathways can produce a greater growth hormone response than activating either pathway independently.

Researchers study this combination to better understand:

• Growth hormone secretion and pituitary signalling
• Hormonal pathways associated with muscle growth and development
• Protein metabolism and tissue regulation
• Growth hormone secretagogue interactions
• Endocrine mechanisms involved in body composition and metabolic function

Although the underlying signalling mechanisms have been studied, clinical evidence demonstrating improved muscle growth, recovery or athletic performance from this specific combination remains limited.

For additional compounds investigated in these areas, explore Coridion Sciences’ collection of peptides for muscle growth and performance, covering research peptides associated with growth hormone activity, muscle physiology and performance-related biological pathways.

Mechanism of Action

CJC-1295 No DAC and GHRP-2 interact with two distinct growth hormone regulatory pathways.

CJC-1295 No DAC: A modified GHRH analogue that activates pituitary GHRH receptors and stimulates intracellular cAMP signalling associated with growth hormone secretion.

GHRP-2: A synthetic growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a), influencing growth hormone release through a separate signalling mechanism.

Research into simultaneous GHRH and ghrelin receptor activation has demonstrated synergistic effects on growth hormone secretion. GHRP-2 may also influence prolactin and cortisol responses, reflecting its broader endocrine activity.

Research Characteristics

• Product: CJC-1295 No DAC + GHRP-2
• Concentration: 5mg + 5mg
• Format: 3ml pen
• Classification: GHRH analogue and growth hormone secretagogue
• Primary research focus: Growth hormone regulation and pituitary signalling
• Secondary research areas: Muscle physiology, protein metabolism and endocrine regulation
• Research mechanisms: GHRH receptor and GHS-R1a activation

Research Use Only

CJC-1295 No DAC + GHRP-2 is supplied exclusively for laboratory and scientific research purposes. It is not approved for human consumption, medical treatment or performance enhancement.

The combination engages two distinct pituitary signalling pathways. Research describes GHRH receptor agonism producing cAMP-mediated stimulation of somatotrophs, while ghrelin receptor (GHS-R1a) agonism acts through a separate pathway involving both direct somatotroph stimulation and suppression of somatostatin tone. Because the two receptors are independent and somatostatin functions as the principal brake on release, studies report that simultaneous engagement produces a response greater than the sum of the individual pathways. Selectivity characteristics differ between the available ghrelin receptor agonists.

Synergy between GHRH and ghrelin receptor pathways is one of the better-replicated findings in secretagogue pharmacology. Research on specific fixed combinations is considerably thinner than research on the underlying principle.

Pathway synergy

Well-replicated research showing greater release from simultaneous GHRH and GHS-R1a engagement.

Somatostatin tone

Studies on ghrelin receptor agonism reducing the principal inhibitory brake on secretion.

GHRP-2 potency

Comparative studies ranking release magnitude above the selective agonists.

Selectivity trade-off

Documented intermediate cortisol and prolactin involvement relative to ipamorelin.

Anti-doping context

Growth hormone secretagogues are listed by anti-doping authorities.